GlobeNewswire

UPDATE -- Trado GmbH Announces That Berlin Court Intervenes and Grants Preliminary Injunction Against Matthias Woestmann and Associates, Who Lost Millions of Envion Investor Money

Dela

Trado GmbH / UPDATE -- Trado GmbH Announces That Berlin Court Intervenes and Grants Preliminary Injunction Against Matthias Woestmann and Associates, Who Lost Millions of Envion Investor Money . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Victory for Envion Founders, As Quadrat Capital and Sycamore GmbH, Controlled by Woestmann, Thomas van Aubel, and Jutta Freifrau von Falkenhausen, Receive Setback

BERLIN, June 07, 2018 (GLOBE NEWSWIRE) -- The following are statements issued by Trado GmbH: Matthias Woestmann and his business associates, through their investment vehicles Quadrat Capital and Sycamore GmbH, received a striking blow on Tuesday from a Berlin judge in a ruling that may be the first of many setbacks for the current majority owners of Swiss blockchain infrastructure company envion AG. A preliminary injunction filed on behalf of envion's founders - led by Michael Luckow through the founders' company Trado GmbH - who claim rightful ownership of envion, was granted on Tuesday, June 5th, 2018.

Actions taken by Woestmann and the others follow a pattern used with previous companies involved in scandals across Germany. Evidence seen by the Berlin court was sufficient for the judge to rule that envion shares cannot be sold or traded to any 3rd party. The ruling further forbids envion's unlawful shareholders from transferring or debiting any of envion's assets. Envion's founders have stated that they will continue to file lawsuits in both German and Swiss courts until their majority is restored. The next court date is scheduled for June 21st.

The owners of the two holding companies (Quadrat Capital GmbH and Sycamore GmbH), Matthias Woestmann, Thomas van Aubel, Jutta Freifrau von Falkenhausen, and Dinnies von der Osten, have a history of profiting from investments in companies that fail spectacularly and under suspicious circumstances. They and their associates are linked to a long list of companies involved in some of Germany's largest financial scandals, including IGB, Balda (renamed to Clere), Q-cells, and Solon. 

Mistakes made while executing the takeover of envion, which raised $100 million in an ICO in January, may keep envion from being their latest victim. Instead of a legal corporate takeover, Woestmann violated a contract which explicitly forbade him from actions compromising the majority ownership of the founders. Woestmann's inaction since the takeover has resulted in millions of dollars in lost dividends for investors and the founders being blocked from operating the company.

"Woestmann's serious missteps now threaten to bring his and his confederates' house of cards crashing down because he illegally created extra shares via an unauthorized capital increase which he then gave to Sycamore," said Michael Luckow, one of the founders of envion who have taken legal action against Woestmann and his associates.

Speaking to Swiss news service SWI, Woestmann did not deny charges that his actions were illegal when he diluted the founders' shares. Envion investors reported that he admitted his guilt in a call on May 28th which was widely discussed within the envion investor community, stating that he expected that he would be found guilty and would be liable for damages. 

When solicitations distributed by Woestmann for bids to buy envion were attained by the founders, they moved quickly to file the court injunction. Documents show Woestmann attempting to sell envion for use as a "holding structure for new businesses to separate envion (sic) balance sheet from profitable businesses" and advertising that the "existing investor base can be used for all kinds of [other] business models" apart from the business that investors supported with $100 million.

About Trado GmbH

Trado GmbH holds the founders' shares in envion AG, a German-Swiss company that has developed a disruptive datacenter concept for crypto mining: a system of container-based mobile units that can be deployed right at the source of energy, either at the solar photovoltaic (PV) park or the power plant, providing the required flexibility for today's energy markets. Information about Trado and envion's founders can be found at www.envion-founders.org. 

Contact:

Chris Pfaff Tech Media LLC
Chris Pfaff
Phone: +1-201-218-0262
Email: chris@chrispfafftechmedia.com 

NAÏMA Strategic Legal Services GmbH
Uwe Wolff
phone: +49 30 2404 8290
email: uwe.wolff@naima-media.de




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Trado GmbH via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum